Biocon introduces therapy for treatment of Hepatitis C in India

Biocon on Thursday announced introduction of an advanced novel therapy for the treatment of Hepatitis C in India – CIMIVIR-L.

biocon shares
The company had posted a net profit of Rs 46.6 crore for the corresponding period of the previous fiscal, Syngene International said in a filing to BSE. (Reuters)

Biocon on Thursday announced introduction of an advanced novel therapy for the treatment of Hepatitis C in India – CIMIVIR-L.

CIMIVIR-L is a once-a-day oral therapy that the company claims will offer a convenient, effective and safe alternative to people infected with Hepatitis C virus. CIMIVIR-L is a fixed dose combination of Ledipasvir 90 mg and Sofosbuvir 400 mg, which is equivalent of the innovator product commercialised by Gilead Sciences in the US.

The Drugs Controller General of India (DCGI) recentle approved the sale of Sofosbuvir-Ledispasvir combination, which is being manufactured in India under licence from Gilead.

Biocon’s CIMIVIR-L will be made available to patients in India at a a fraction of the global cost of the innovator brand. The cost of a 12-week course of this combination therapy in the US is $94,500 (around Rs 63 lakhs).

Ravi Limaye, president – marketing, Biocon said, “The introduction of CIMIVIR-L will strengthen Biocon’s current porfoli of Virology products. It furthers our commitment to offer affordable therapy of unmet patient needs in debilitating and life-threatening conditions.”

Shares of the company were trading 5.24 per cent up at Rs 507.00 in morning trade.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express Telegram Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.